Literature DB >> 31169091

Parotid gland carcinoma: 32 years' experience from a single institute.

T Nakano1,2, R Yasumatsu1, R Kogo1, K Hashimoto1, K Asai3, S Ohga3, H Yamamoto4, T Nakashima5, T Nakagawa1.   

Abstract

BACKGROUND: Parotid gland carcinoma is a rare and complicated histopathological classification. Therefore, assembling a sufficient number of cases with long-term outcomes in a single institute can present a challenge.
METHOD: The medical records of 108 parotid gland carcinoma patients who were treated at Kyushu University Hospital, Fukuoka, Japan, between 1983 and 2014 were reviewed. The survival outcomes were analysed according to clinicopathological findings.
RESULTS: Forty-six patients had low clinical stage tumours (I-II), and 62 patients had high clinical stage tumours (III-IV). Fifty-two, 10 and 46 patients had low-, intermediate- and high-grade tumours, respectively. Twenty-seven of 65 cases had positive surgical margins. In high clinical stage and intermediate- to high-grade tumours, adjuvant radiation therapy was correlated with local recurrence-free survival (p = 0.0244). Intermediate- to high-grade tumours and positive surgical margins were significantly associated with disease-specific survival in multivariate analysis (p = 0.0002 and p = 0.0058).
CONCLUSION: The results of this study show that adjuvant radiation therapy is useful for improved local control in patients with high clinical stage and intermediate- to high-grade tumours.

Entities:  

Keywords:  Neoplasm Recurrence, Local; Prognoses; Radiotherapy, Adjuvant; Salivary Gland Cancer

Mesh:

Year:  2019        PMID: 31169091     DOI: 10.1017/S0022215119001130

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  3 in total

1.  Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland Cancer.

Authors:  Takafumi Nakano; Ryuji Yasumatsu; Kazuki Hashimoto; Ryosuke Kuga; Takahiro Hongo; Hidetaka Yamamoto; Mioko Matsuo; Takahiro Wakasaki; Rina Jiromaru; Tomomi Manako; Satoshi Toh; Muneyuki Masuda; Moriyasu Yamauchi; Yuichiro Kuratomi; Hideoki Uryu; Torahiko Nakashima; Akihiro Tamae; Risa Tanaka; Masahiko Taura; Toranoshin Takeuchi; Takamasa Yoshida; Takashi Nakagawa
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

2.  Nomogram Predicting Cancer-Specific Death in Parotid Carcinoma: a Competing Risk Analysis.

Authors:  Xiancai Li; Mingbin Hu; Weiguo Gu; Dewu Liu; Jinhong Mei; Shaoqing Chen
Journal:  Front Oncol       Date:  2021-10-13       Impact factor: 6.244

Review 3.  Estimating survival after salvage surgery for recurrent salivary gland cancers: Systematic review.

Authors:  Giuditta Mannelli; Lara V Comini; Andrea Sacchetto; Roberto Santoro; Giuseppe Spinelli; Pierluigi Bonomo; Isacco Desideri; Paolo Bossi; Ester Orlandi; Giammarco Alderotti; Alessandro Franchi; Annarita Palomba; Albino Eccher; Daniele Marchioni; Riccardo Nocini; Cesare Piazza; Gabriele Molteni
Journal:  Head Neck       Date:  2022-04-20       Impact factor: 3.821

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.